Previous Article | Next Article 
Infection and Immunity, January 2001, p. 262-270, Vol. 69, No. 1
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.1.262-270.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Development of a Recombinant Antigen Vaccine against Infection
with the Filarial Worm Onchocerca volvulus
David
Abraham,1,*
Ofra
Leon,1
Shalom
Leon,1 and
Sara
Lustigman2
Department of Microbiology and Immunology,
Thomas Jefferson University, Philadelphia, Pennsylvania
19107,1 and The Lindsley F. Kimball
Research Institute, New York Blood Center, New York, New York
100212
Received 16 June 2000/Returned for modification 4 August
2000/Accepted 11 October 2000
 |
ABSTRACT |
Efforts to control Onchocerca volvulus, the etiologic
agent of river blindness, have been limited to vector control
and drug treatment to eliminate microfilariae, with no means available to prevent infection. The goal of this study was to develop a vaccine
against this infection using recombinant antigens that are expressed in
the early larval stages of the parasite. Five recombinant antigens,
Ov7, Ov64, OvB8, Ov9M, and Ov73k, were identified by
screening adult and larval cDNA libraries with antibodies from immune
humans, chimpanzees, or rabbits. When mice were immunized with
the five individual recombinant antigens, statistically significant reductions in parasite survival were induced in mice immunized with Ov7, OvB8, or Ov64, when administered in alum but not when injected in Freund's complete adjuvant (FCA). Live larvae recovered from control and immunized mice were analyzed to determine their developmental stages. A decrease in the percentage of larvae molting from the third stage to the fourth stage was observed with mice immunized with Ov7, Ov64, or OvB8 in alum but not with mice immunized with Ov9 and Ov73k or with mice immunized with any of the five antigens
in FCA. Mice immunized with a cocktail of the three protective antigens
developed protective immunity equal to that seen with mice immunized
with individual antigens. This study has identified, for the first
time, three recombinant antigens capable of inducing protective immunity to O. volvulus. Furthermore, since the
antigens functioned with alum as the adjuvant, this vaccine could
potentially be used clinically to prevent river blindness in humans.
 |
INTRODUCTION |
Onchocerca volvulus, the
etiologic agent of river blindness, infects about 20 million people in
Africa and South America and is a leading cause of infectious blindness
globally (21). Infections with O. volvulus are
initiated by the feeding of an infected blackfly on a human, during
which time infective third-stage larvae (L3) are released onto the skin
and subsequently develop into adult worms. Vector- and
chemotherapy-based control methods are used in many regions of
endemicity (21), but because of many factors including the
development of drug resistance, the high cost of the programs, and
inaccessibility of the 10 to 15 years of required treatment with
ivermectin to much of the infected population, these control methods
have limited applicability.
Human populations in which the infection is endemic have provided
evidence that naturally acquired immunity against O. volvulus infection can occur. Within regions where onchocerciasis
is endemic, 1 to 5% of the population who have been exposed to the
infection display no signs or symptoms of the infection; these
individuals are considered to be immune to the disease and have been
termed putatively immune (PI) individuals (16, 20, 52). In
addition, the number of microfilariae found in the skin of infected
individuals tends to level off between 20 and 40 years of age, which
suggests an acquired means of limiting infections (14).
Efforts to understand the mechanism of protective immunity in humans
have yielded conflicting results. Some studies have concluded that
protective immunity in the PI individuals was correlated with
diminished specific immunoglobulin E (IgE), IgG, and IgG subclass
responses and an enhanced production of interleukin 2 (IL-2) and gamma
interferon (IFN-
) in response to adult worm antigens. This profile
suggested that protective immunity was dependent on Th1 responses
(32, 36, 42, 47, 48). In other studies, PI individuals
produced IL-2, IL-5, and granulocyte-macrophage colony-stimulating
factor in response to adult worm antigens and thus exhibited a mixed Th1 and Th2 response (10). Different results were obtained
when cytokine responses to larval antigens were compared to responses to adult or microfilarial antigens. The PI individual response to
larval antigens demonstrated a significant elevation of both IL-5 and
granulocyte-macrophage colony-stimulating factor in comparison to
levels in infected individuals. Additionally, a subgroup of PI
individuals also had a significantly elevated IFN-
response to
larval antigens. These findings suggested that the response of PI
individuals to larval antigens was Th2 in the group as a whole, with a
mixed Th1-Th2 response in a subgroup. In contrast, the response to
adult and microfilarial antigens in the same PI population was limited
to IL-5 (51). This finding further confounds the answer to
the question of what type of immune response is associated with
protective immunity in humans.
Protective immunity to larval O. volvulus has been
demonstrated in two animal models, chimpanzees and mice. These animals were immunized with irradiated L3 because this form of immunization was
proven effective elsewhere in several filarial host-parasite systems
(3, 5, 41, 46, 54). One out of four chimpanzees immunized
with irradiated O. volvulus L3 and then infected with untreated L3 demonstrated protective immunity based on the number of
microfilariae found in the skin (44). A mouse model for
the study of immunity to larval O. volvulus also
demonstrated that immunization with irradiated larvae induced
protective immunity, killing approximately 50 to 80% of challenge
larvae. Diffusion chambers were used in the mouse model to contain the
larvae and thus afford an efficient method for recovery of the
parasites and for analysis of the micro environment in which the
parasites were found. Cellular infiltrate into diffusion chambers
implanted in immunized mice contained high numbers of eosinophils
(33). Protective immunity in the mice to larval O. volvulus was dependent on IL-4 and IL-5 and not IFN-
(28,
34). These findings clearly demonstrated that the protective
immune response induced by irradiated larvae in mice was Th2 dependent.
The objective of the present study was to determine the efficacy of
recombinant antigens as vaccine candidates against the larval
stages of O. volvulus. Studies with other filarial
worms have shown that recombinant antigens can be identified with
antibodies from immune serum and that these antigens induced a
protective immune response against larval parasites, killing
approximately 50% of parasites in the challenge infections (26,
35, 49). The advantage of using defined recombinant antigens
lies in the fact that they can be efficiently and reproducibly
generated, whereas irradiated larvae or crude native antigen
preparations cannot be practically generated and therefore lack
clinical utility. Four recombinant antigens (Ov7, Ov64, OvB8, and
Ov73k) were selected in the present study for vaccine efficacy testing
based on their recognition by antibodies from PI individuals or
immunized chimpanzees, and one (Ov9M) was selected based on recognition
by antibodies from rabbits immunized with L3 and fourth-stage larvae
(L4) (Table 1). Additional criteria for
selection of these antigens were their expression in L3 and/or L4 and
their high immunogenicity in PI or infected individuals from Liberia,
Ecuador, and Cameroon. Ov7 was recognized by 65 to 90% of these
individuals, Ov64 was recognized by 88 to 95%, OvB8 was recognized by
31 to 58%, Ov73k was recognized by 90 to 100%, and Ov9M was
recognized by 59 to 80% (S. Lustigman, personal communication).
The five recombinant antigens were tested in the present study to
determine their ability to induce in mice the killing of a challenge
infection consisting of O. volvulus larvae implanted in a
diffusion chamber. The antigens were injected into the mice using
either Freund's complete adjuvant (FCA) or alum as the adjuvant. FCA
was selected because it preferentially induces Th1 responses, whereas
alum preferentially induces Th2 responses (17, 31, 55). It
was determined that three of the five antigens induced protective
immunity when injected in alum and that combining the three antigens
into one vaccine cocktail did not enhance the level of protective
immunity that was induced.
 |
MATERIALS AND METHODS |
Expression of the recombinant proteins.
Ov64 cDNA and the
OvB8 clones were expressed in the pGEX-4T-3 vector, Ov7 and Ov9M were
expressed in the pGEX-1N vector, and Ov73k was expressed in the pGEX-1T
vector (Amersham Pharmacia Biotech, Piscataway, N.J.). Large-scale
production and purification of each of the recombinant
Schistosoma japonicum glutathione S-transferase (GST) fusion polypeptides were carried out according to the procedure previously described (38). The recombinant proteins were
dialyzed against phosphate-buffered saline (PBS) and sterilized by
passage through a 45-µm-pore-size filter. Ov7 was also expressed as a secreted polypeptide in Saccharomyces cerevisiae using the
pAB125 plasmid vector, a gift from Chiron Corp., Emeryville, Calif.
Following a preparation of the plasmid DNA in Escherichia
coli, this construct was digested with BamHI and
SalI, releasing a fragment containing the yeast expression
vector pBS24.1 used to transform yeast spheroplasts, as previously
described (9, 50). Transformed yeast cells were selected
on a leucine-deficient medium plate. Colonies were picked up and
subcultured in leucine-deficient minimal synthetic defined liquid
medium (Clontech Laboratories, Inc., Palo Alto, Calif.) containing 8%
glucose to prevent induction. The overnight culture was subsequently
diluted into YEPD (1% Bacto Yeast Extract and 2% Bacto Peptone plus
1% glucose medium). The secreted Ov7 was purified from the yeast
culture supernatant after centrifugation by ion-exchange chromatography
(Q-Sepharose Fast Flow; Pharmacia). The culture supernatant was
precipitated with 20% (wt/vol) polyethylene glycol 1000 and
resuspended in 10 mM Tris, pH 8.0, before being loaded on the
Q-Sepharose column. Bound protein was eluted with a linear gradient of
0 to 0.5 M NaCl in 10 mM Tris, pH 8.0. The fractions containing Ov7
were detected by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and Western blotting using affinity-purified monospecific human antibodies directed against recombinant Ov7. The
specific fractions were collected and dialyzed against 10 mM Tris, pH
8.0.
Electron microscopy.
O. volvulus L3 were placed
in culture for 4 days, as previously described (39), to
obtain larvae in the process of molting from L3 to L4. The larvae were
fixed for 30 min in 0.25% glutaraldehyde in 0.1 M phosphate buffer, pH
7.4, containing 1% sucrose, and were then processed for immunoelectron
microscopy. For the immunolocalization of the parasite antigens
corresponding to the five recombinant antigens, thin sections of
embedded worms were incubated with affinity-purified antibodies against
each of the individual antigens, followed by incubation with a
suspension of 15-nm gold particles coated with protein A, as described
previously (25, 37, 40). In addition, thin sections of
molting L3 were probed with normal mouse serum and serum obtained from
mice immunized with irradiated L3 and which developed protective
immunity to challenge infections (33). Sections were
incubated with the immune mouse serum, followed by rabbit anti-mouse Ig
before reaction with 15-nm gold particles coated with protein A.
Immunization protocols.
Male BALB/cByJ mice, 6 to 8 weeks
old, were obtained from Jackson Laboratory (Bar Harbor, Maine). Animals
were housed in Micro-Isolator boxes (Lab Products, Inc., Maywood, N.J.)
and were fed autoclavable laboratory rodent chow (Ralston Purina, St.
Louis, Mo.) and sterilized acid water (pH 2.7) ad libitum. The animal
housing room was temperature, humidity, and light cycle controlled.
In the initial screening of the antigens, 25 µg of each antigen in
0.1 ml of PBS was injected subcutaneously into the nape of the neck
with either 0.1 ml of FCA (Sigma Chemical Co., St. Louis, Mo.) or 0.1 ml of low-viscosity alum, 2 mg/ml in PBS (Reheis Inc., Berkeley
Heights, N.J.). A booster immunization followed 14 days later with the
same quantity of antigen either in Freund's incomplete adjuvant for
mice initially injected with FCA or in alum, as described above. In
subsequent experiments, mice were immunized with 2, 25, or 50 µg of
the antigens with alum, to determine the optimal dose. Finally,
experiments were performed in which a mixture of three antigens was
prepared, with 25 µg of each antigen, and the animals were immunized
with 75 µg of the antigen mixture in alum, as described above,
followed by a booster immunization with the same materials.
Challenge infections in diffusion chambers.
Cryopreserved L3
were prepared in Cameroon by the following method. Black flies
(Simulium damnosum) were fed on consenting donors infected
with O. volvulus, and after 7 days the developed L3 were
collected from dissected flies, cleaned, and cryopreserved in dimethyl
sulfoxide and sucrose using Biocool II computerized freezing equipment
(FTS Systems Inc., Stone Ridge, N.Y.) as previously described
(13). Cryopreserved L3 were thawed by placing tubes containing the L3 on dry ice for 15 min followed by immersion in a
37°C water bath. The L3 were then washed five times in a 1:1 mixture
of Iscove's modified Dulbecco's medium and NCTC-135 with 100 U of
penicillin, 100 µg of streptomycin, 100 µg of gentamicin, and 30 µg of chloramphenicol (Sigma Chemical Co.) per ml.
Diffusion chambers were constructed from 14-mm-diameter Lucite rings
and covered with 5.0-µm-pore-size hydrophilic Durapore membranes
(Millipore, Bedford, Massa.) as previously described (7).
Twenty-five O. volvulus L3 in Iscove's modified Dulbecco's medium-NCTC-135 with antibiotics were inserted into each diffusion chamber prior to implantation in mice. The animals were anesthetized with inhaled isoflurane, and a subcutaneous pocket was formed in the
rear flank of each mouse. A single diffusion chamber containing 25 live
O. volvulus L3 was inserted into each pocket.
Diffusion chambers were recovered 21 days postchallenge. At the time of
diffusion chamber recovery, mice were anesthetized with methoxyflurane
(Pitman-Moore, Inc., Mundelein, Ill.) and then killed by
exsanguination. Serum was then prepared for subsequent antibody
analyses. Diffusion chamber contents were analyzed to assess larval
survival and the nature of the cellular infiltration into the diffusion
chamber. Larvae recovered from diffusion chambers were considered live
if they exhibited motility. Live larvae were placed into 70% ethanol
containing 5% glycerol at 60°C. Ethanol was allowed to evaporate,
leaving the larvae in glycerol. The larvae were then analyzed
microscopically to differentiate L3 from L4. The following criteria
were used: (i) the anterior end of the L4 is rounded whereas the
anterior end of the L3 narrows; (ii) the genital primordium is visible
only in the L4; (iii) the posterior end of the L4 exhibits a clearly
visible anus, whereas that of the L3 does not; and (iv) the
cuticle-body wall of the L4 is significantly thicker than that of the
L3 (6). Cells found within the diffusion chambers were
collected by centrifugation onto slides using a Cytospin 3 (Shandon
Inc., Pittsburgh, Pa.) centrifuge and then stained for differential
counts with DiffQuik (Baxter Healthcare Corp., Miami, Fla.).
ELISA.
Serum levels of antigen-specific IgG1, IgG2a, and IgE
antibodies were measured by enzyme-linked immunosorbent assay (ELISA). Fifty microliters of a solution containing 2 µg of recombinant antigen per ml in 50 mM Tris-Cl (pH 8.8) was placed in the wells of
96-well Maxisorp plates (Nalge Nunc International, Rochester, N.Y.)
overnight. After washing, 200 µl of blocking buffer (0.17 M boric
acid, 0.12 M NaCl, 1 mM EDTA, 0.25% bovine serum albumin, 0.05% Tween
20, pH 8.5) (BBS) was added to each well. Individual sera were diluted
in BBS, 1/200 for IgG1 and 1/3 for IgG2a and IgE, and then added to the
wells, followed by biotinylated anti-mouse IgG1, IgG2a, or IgE
(Pharmingen, San Diego, Calif.) diluted 1:250. Extravidin peroxidase
diluted 1:1,000 (Sigma) was added to the wells followed by ABTS
[2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid); Kirkegaard & Perry
Laboratories, Gaithersburg, Md.]. Optical densities were read at 410 nm in a Dynatech MR500 ELISA reader (Dynatech Laboratories, Inc.,
Chantilly, Va.) after overnight incubation.
Statistical analyses.
Data were analyzed by multifactorial
analysis of variance in Systat 5.2 (Systat, Inc., Evanston, Ill.).
Probability values of less than 0.05 were considered significant. All
experiments were performed a minimum of two times with five to six
animals per group, except the measurements of dose response, which were done once. Data from representative experiments are presented in the
tables and figures. Percent reduction was calculated as follows: % reduction = [(average worm survival in control mice
average worm survival in immunized mice)/average worm survival in
control mice] × 100.
 |
RESULTS |
Comparative localization of the recombinant proteins in L3.
Antibodies from mice which developed protective immunity after
immunization with irradiated L3 bound to parasite antigens in the
region where the cuticle separates during molting from L3 to L4 (Fig.
1A), the channels
connecting the esophagus to the cuticles (Fig. 1B), and the basal
lamina surrounding the esophagus and the body cavity (Fig. 1C). Native
parasite proteins corresponding to Ov7, Ov64, OvB8, and Ov73k
recombinant proteins were found in regions compatible with those
identified by the antibodies from the immunized mice (Fig.
2). Specifically, Ov7
(Fig. 2A) and Ov73k (Fig. 2D) were seen in the region of the cuticles
where separation occurs and Ov64 (Fig. 2B) was seen in the cuticle. Ov7, Ov64, OvB8, and Ov73k (Fig. 2A to D) were found in the channels connecting the esophagus and the cuticles. Finally, OvB8 (Fig. 2D) was
prominent at the basal lamina surrounding the esophagus and the body
cavity in molting larvae, and antibodies against Ov9M reacted with the
calponin protein in the muscles (Fig. 2E).

View larger version (70K):
[in this window]
[in a new window]
|
FIG. 1.
Ultrastructural localization by immunoelectron
microscopy of parasite proteins recognized by antibodies from
mice that developed protective immunity after immunization with
irradiated L3. Thin sections of O. volvulus larvae during molting of
L3 to L4 in vitro were incubated first with mouse antibodies and then
with rabbit anti-mouse Ig antibodies followed by protein A coupled to
15-nm gold particles for indirect antigen localization (bars, 0.5 nm).
Note the labeling in the regions where the cuticles of L3 (arrowheads)
and L4 (arrows) separate (A), the channels (small arrowheads)
connecting the esophagus to the cuticle (B), and the basal lamina (open
arrowheads) surrounding the esophagus and the body cavity (C). Labeling
was not observed in sections incubated in normal mouse serum (D).
|
|

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 2.
Ultrastructural localization by immunoelectron
microscopy of the parasite proteins corresponding to Ov7, Ov64, OvB8,
Ov73k, and Ov9M recombinant proteins. Thin sections of O. volvulus larvae during molting of L3 to L4 in vitro were incubated
first with antibodies raised against GST-Ov7 (A), GST-Ov64 (B),
GST-OvB8 (C), GST-Ov73k (D), and GST-Ov9M (E) fusion polypeptides and
then with protein A coupled to 15-nm gold particles for indirect
antigen localization (bars, 0.5 nm). Note the labeling in the areas of
the L4 epicuticle-cuticle (small arrows, panels A and D) and the basal
layer of the L3 cuticle (arrowheads, panels A and D) where the
separation between cuticles takes place, the cuticle of L3 day 1 (B),
channels connecting the esophagus (Eo) and the cuticle (small
arrowheads, panels A to D), the basal lamina (open arrowheads)
surrounding the esophagus and the body cavity (C and D), and muscles
(Mu) (E). Serum raised against GST did not ross-react with any proteins
in the larvae (data not shown).
|
|
Immunization with individual recombinant antigens.
Mice
immunized with either Ov7, Ov64, OvB8, Ov9M, or Ov73k received
challenge infections consisting of O. volvulus L3 implanted subcutaneously in diffusion chambers. After 3 weeks, the number of live
larvae recovered from each diffusion chamber was counted. Statistically
significant reductions in parasite survival were induced by three of
the antigens, Ov7, OvB8, and Ov64, when administered in alum.
Immunization with Ov7, Ov9M, or Ov73k induced some reduction in
parasite survival when injected with FCA; however, the reductions did
not reach statistical significance compared to those for controls (Table 2).
Live larvae recovered from control and immunized mice were analyzed to
determine whether they were L3 or if they had successfully molted into
L4. A significant reduction was seen in the percentage of larvae that
were recovered as L4 from mice immunized with Ov7, Ov64, or OvB8 (Table
2). The actual number of live L3 recovered from the control mice was
compared to the number recovered from mice immunized with these three
antigens. It was determined that both groups of mice maintained small,
but equal, numbers of L3. The decrease in live parasites recovered from
mice immunized with Ov7, Ov64, or OvB8 in alum was therefore a
reflection of a decrease in the number of L4 and not L3 in immunized mice.
Analyses were performed to identify immune factors that could be
correlated with the development of protective immunity. Diffusion chamber contents were analyzed to determine the cell types that migrated into the microenvironment of the larvae. No differences were
observed in the types of cells or in the numbers of cells found in the
diffusion chambers either between control and immunized mice or between
mice immunized with antigens in FCA and mice immunized with antigens in
alum. In all groups, the cells consisted of approximately 45%
neutrophils, 40% monocytes, 10% lymphocytes, and 5% eosinophils.
IgG1 and IgE antigen-specific antibody levels were measured to assess
Th2 responses, and IgG2a antibody levels were measured to assess Th1
responses. In general, immunized mice responded to the five antigens at
levels significantly higher than that seen with control mice for all
three antibody classes or subclasses tested. Antigens administered with
alum induced Th2-associated antibodies, whereas FCA did not
consistently induce antibodies associated with the Th1 response.
Differences in antibody responses were noted, however, based on the
antigen used in the immunization. Ov7 induced elevated IgG1 and IgE
levels regardless of the adjuvant used; IgG2a antibodies were
undetectable even when FCA was used as the adjuvant. OvB8 induced weak
antibody responses for all antibody isotypes tested with both
adjuvants. Ov64, Ov9M, and Ov73k induced IgG1 antibody responses when
alum and FCA were used as the adjuvants, and an IgG2a response when FCA
was used (Fig. 3).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
IgG1, IgE, and IgG2a antibody responses of mice
immunized with Ov7, Ov64, OvB8, Ov9M, or Ov73k with either alum or FCA.
The mean responses measured for control mice were subtracted from the
responses measured for individual immunized mice. Values presented are
the means and standard deviations of the measurements from the
immunized mice after subtraction of the control values. Asterisks
represent significant differences between responses seen for mice
immunized with alum and those for mice immunized with FCA.
|
|
Immunization with a mixture of recombinant antigens.
The goal
of the next series of experiments was to determine the optimal regimen
for immunizing mice with Ov7, Ov64, and OvB8 in alum. The first
objective was to determine the optimal dose for immunization with the
three antigens. Mice were immunized with the three individual antigens
in alum at doses of 2, 25, and 50 µg and challenged as described
above. All of the doses tested for the three antigens induced
protective immunity at comparable rates. It was next hypothesized that
immunization of mice with a mixture of the three protective antigens
would lead to a protective immune response that would exceed that
induced by any of the antigens individually. Mice were immunized either
with individual antigens at 25 µg per dose or with a cocktail
composed of equal concentrations of the three antigens, also at 25 µg
of each antigen per dose. The dose of 25 µg was selected because it
was as effective as 2 and 50 µg at inducing protective immunity and
because this dose of the antigens was effective at inducing protective
immunity in repeated experiments. Mice immunized with the cocktail of
antigens developed protective immunity equal to, but not greater than, that in mice immunized with individual antigens (Table
3). IgG1 and IgE antigen-specific
antibody levels were measured in mice immunized with individual
antigens or with the cocktail of three antigens. IgG1 responses to Ov7
were significantly elevated in mice immunized with the antigen cocktail
compared to responses in mice immunized with Ov7 alone. In contrast,
IgG1 levels in response to OvB8 in mice immunized with the cocktail
were significantly reduced compared to the levels seen with mice
immunized with the single antigen. Significantly lower antigen-specific
IgE responses to Ov7 and Ov64 were obtained in mice immunized with the
antigen cocktail than in mice immunized with the individual antigens
(Fig. 4).
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Effect of immunization with single antigens or a
cocktail of three recombinant antigens in alum on the survival of
larvae in challenge infectionsa
|
|

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 4.
IgG1 and IgE antibody responses of mice immunized with
Ov7, Ov64, and OvB8, with alum injected individually or as a cocktail
of three antigens. The mean responses measured for control mice were
subtracted from the responses measured for individual immunized mice.
Values presented are the means and standard deviations of the
measurements from the immunized mice after subtraction of the control
values. Asterisks represent significant differences between responses
seen for mice immunized with single antigens and those for mice
immunized with three antigens.
|
|
 |
DISCUSSION |
The objective of this study was to test the hypothesis that
antigens identified by antibodies from humans or animals with protective immunity to O. volvulus would induce a protective
immune response to the homologous parasite in mice. The five antigens used in this study were selected using a variety of criteria including the following: (i) the proteins were expressed in L3 and L4, (ii) they
were identified by antibodies found in PI individuals or in immunized
animals, (iii) they were recognized by a high percentage of PI and
infected individuals from different geographic locations, and (iv) the
anatomical locations of these proteins in the larvae were coincident
with the binding sites of antibodies from mice with protective immunity
to the parasite. Three of the five antigens in alum as the adjuvant
induced a protective immune response as determined by the killing of 34 to 46% of challenge larvae in repeated experiments. This level of
parasite reduction is comparable to the results obtained for mice
immunized with irradiated O. volvulus larvae (33,
34). The present study has thus demonstrated that
immunoscreening can identify antigens that function effectively in a
vaccine. The three protective antigens were identified by antibodies
from PI individuals or an immunized chimpanzee and yet functioned as
successful immunogens in mice, a third host species. It was therefore
concluded that antigen recognition and action were not host specific
but rather that the antigens induced protective immunity regardless of
the exposed host species.
It was further concluded that the protective immune response induced by
the three recombinant antigens was directed at larvae molting from L3
to L4 or at L4 and was not effective at killing L3. The basis for this
conclusion was that there was no decrease in the number of surviving L3
in immunized mice, whereas there was a significant decrease in the
number of L4. Evidence from Acanthocheilonema viteae
(8, 15), Dirofilaria immitis (4), and Strongyloides stercoralis (11, 12) supports
the hypothesis that larval nematodes need to develop in vivo before
they become susceptible to immune-mediated killing. Larvae may become
more susceptible to the killing process during or after the molt from L3 to L4 or after the larvae have adapted to survival under mammalian host conditions. Based on this conclusion, the level of larval killing
in immunized mice would actually be higher than that reported in this
study, since all of the remaining L3 would be killed when they molted
into L4. Evidence from immunization trials against D. immitis in dogs has shown that the protective immune response killed approximately 50% of challenge larvae at 3 weeks postchallenge but killed 98% at 6 months postchallenge (23). It is
therefore probable that the level of protective immunity induced by the recombinant antigens in the present study would be augmented if the
challenge infection larvae were recovered at a later time point.
The three protective antigens functioned only when injected with alum
and not when injected with FCA, suggesting that the immune-mediated
resistance was of the Th2 type and not Th1. This conclusion was based
on previous reports which showed that FCA preferentially induced Th1
responses, while alum induced Th2 responses (17, 31, 55).
The finding that protective immunity induced by recombinant antigens
was dependent on a Th2 response complements the results obtained with
irradicated L3 immunization. Immunity to O. volvulus larvae
induced by irradiated larvae was dependent on IL-4 and IL-5 (28,
34) and was associated with the presence of eosinophils
(34), thus demonstrating a dependence on Th2 immunity.
Analyses of the antibody isotype responses and of the composition of
the cellular infiltrates failed to confirm that the use of FCA and alum
did induce Th1 and Th2 responses, respectively. Alum consistently
induced Th2-dependent antibodies, but there was an absence of an
increase in eosinophils in the diffusion chambers recovered from
immunized mice. Use of FCA as the adjuvant induced only Th1 antibodies
with three of the tested antigens. An explanation for the failure to
see clear Th1 or Th2 responses induced by the antigens injected with
FCA or alum may be that the three protective antigens each had unique
capabilities of inducing immunity that were modified to varying degrees
by the adjuvants. Immunization of mice against Trichinella
spiralis using four different adjuvants, including FCA and alum,
revealed that the adjuvants did not modify the immune response
qualitatively but did affect the magnitude of the response
(45). Each of the three protective antigens identified in
the present study had its own inherent immune predisposition. Ov7
induced Th2 responses regardless of the adjuvant, OvB8 induced very
weak antibody responses regardless of the adjuvant, and Ov64 induced
Th2 responses in the presence of alum and Th1 responses in the presence
of FCA. Yet, all three antigens induced protective immunity only when injected with alum.
No conclusion could be drawn from this study regarding the mechanism
that the adaptive immune response uses to kill the larvae after
immunization with the recombinant antigens. It must be emphasized, however, that each of the protective antigens is biochemically unique
and that they are found in different anatomical locations. The killing
mechanism induced by each of the antigens may, therefore, be different
and specific for each particular target. Evidence from in vitro studies
suggests that killing of O. volvulus larvae and prevention
of molting of L3 to L4 are mediated by antibody from PI individuals in
collaboration with neutrophils (27). Furthermore,
monospecific affinity-purified human anti-Ov7 antibody, in the presence
of neutrophils, caused a 100% inhibition of molting from L3 to L4 (S. Lustigman, personal communication). Filarial larval growth or
developmental retardation in immunized animals has been reported
previously for the larvae of A. viteae (8), Brugia malayi (3), D. immitis
(1, 2), and Litomosoides carinii
(53). A similar mechanism may be operative in vivo in mice
immunized with recombinant antigens in the present study.
Combining the three protective antigens in one immunization dose did
not induce levels of parasite killing that were greater than that for
any of the single-antigen immunizations. The antigens in the present
study may not have acted synergistically because one was either
immunodominant or immunosuppressive. This hypothesis was supported by
the observed alteration in the antibody responses to the three antigens
dependent on whether they were injected individually or in a cocktail.
This observation suggested that the combination of the three antigens
did not allow a complete immune response to develop to any one of them.
An alternative explanation for this finding is that the adaptive immune
response is capable of killing only a fixed percentage of challenge
larvae. The theoretical basis for this hypothesis is that there is
stage specificity in the protective immune response. Larvae can be
killed only during a limited period of their development, after which the larvae become resistant to attack by the immune response. The fixed
number of larvae killed in the immunized mice might reflect the
percentage of parasites incapable of developing into an immunologically
resistant stage.
In conclusion, this study has demonstrated for the first time that
cross-species identification of antigens by immunoscreening is a
successful method for the selection of vaccine candidates against
O. volvulus. Furthermore, it has shown that the method of
delivery of the antigens is critical in determining the efficacy of a
particular antigen in a vaccine. Three antigens that, with alum,
induced reproducible levels of protective immunity have been
identified. Further study is required to determine the optimal delivery
method for each of these antigens, as well as the mechanism that each
of these antigens induces for the killing of the larval parasites.
Finally, the facts that the antigens functioned with alum as the
adjuvant and that the three antigens are not homologous with any known
human antigens, suggest that this vaccine could be used clinically to
prevent river blindness in humans.
 |
ACKNOWLEDGMENTS |
This work was supported in part by grants from the Edna McConnell
Clark Foundation and the National Institutes of Health (AI42328).
We acknowledge the enthusiastic and essential assistance of Anna Marie
Galioto, De'Broski Herbert, Laura Kerepesi, and Chun-Chi Wang at
Thomas Jefferson University; Jing Liu at the New York Blood Center for
the production of the recombinant Ov7 protein in yeast; and the
excellent technical assistance of Christine Christian and Margaret
Brown in J. McKerrow's laboratory.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, Thomas Jefferson University, 233 South
10th St., Philadelphia, PA 19107. Phone: (215) 503-8917. Fax: (215) 923-9248. E-mail: David.Abraham{at}mail.tju.edu.
Editor:
: J. M. Mansfield
 |
REFERENCES |
| 1.
|
Abraham, D., and R. B. Grieve.
1990.
Genetic control of murine immune responses to larval Dirofilaria immitis.
J. Parasitol.
76:523-528[CrossRef][Medline].
|
| 2.
|
Abraham, D., and R. B. Grieve.
1991.
Passive transfer of protective immunity to larval Dirofilaria immitis from dogs to BALB/c mice.
J. Parasitol.
77:254-257[CrossRef][Medline].
|
| 3.
|
Abraham, D.,
R. B. Grieve,
J. M. Holy, and B. M. Christensen.
1989.
Immunity to larval Brugia malayi in BALB/c mice: protective immunity and inhibition of larval development.
Am. J. Trop. Med. Hyg.
40:598-604.
|
| 4.
|
Abraham, D.,
R. B. Grieve, and M. Mika-Grieve.
1988.
Dirofilaria immitis: surface properties of third- and fourth-stage larvae.
Exp. Parasitol.
65:157-167[CrossRef][Medline].
|
| 5.
|
Abraham, D.,
R. B. Grieve,
M. Mika-Grieve, and B. P. Seibert.
1988.
Active and passive immunization of mice against larval Dirofilaria immitis.
J. Parasitol.
74:275-282[CrossRef][Medline].
|
| 6.
|
Abraham, D.,
A. M. Lange,
W. Yutanawiboonchai,
M. Trpis,
J. W. Dickerson,
B. Swenson, and M.L. Eberhard.
1993.
Survival and development of larval Onchocerca volvulus in diffusion chambers implanted in primate and rodent hosts.
J. Parasitol.
79:571-582[CrossRef][Medline].
|
| 7.
|
Abraham, D.,
H. L. Rotman,
H. F. Haberstroh,
W. Yutanawiboonchai,
R. A. Brigandi,
O. Leon,
T. J. Nolan, and G. A. Schad.
1995.
Strongyloides stercoralis: protective immunity to third-stage larvae in BALB/cByJ mice.
Exp. Parasitol.
80:297-307[CrossRef][Medline].
|
| 8.
|
Abraham, D.,
D. J. Weiner, and J. P. Farrell.
1986.
Protective immune responses of the jird to larval Dipetalonema viteae.
Immunology
57:165-169[Medline].
|
| 9.
|
Barr, P. J.,
H. L. Gibson,
V. Enea,
D. E. Arnot,
M. R. Hollingdale, and V. Nussenzweig.
1987.
Expression in yeast of a Plasmodium vivax antigen of potential use in a human malaria vaccine.
J. Exp. Med.
165:1160-1171[Abstract/Free Full Text].
|
| 10.
|
Brattig, N.,
C. Nietz,
S. Hounkpatin,
R. Lucius,
F. Seeber,
U. Pichlmeier, and T. Pogonka.
1997.
Differences in cytokine responses to Onchocerca volvulus extract and recombinant Ov33 and OvL3-1 proteins in exposed subjects with various parasitologic and clinical states.
J. Infect. Dis.
176:838-842[Medline].
|
| 11.
|
Brigandi, R. A.,
H. L. Rotman,
O. Leon,
T. J. Nolan,
G. A. Schad, and D. Abraham.
1998.
Strongyloides stercoralis host-adapted third-stage larvae are the target of eosinophil-associated immune-mediated killing in mice.
J. Parasitol.
84:440-445[CrossRef][Medline].
|
| 12.
|
Brigandi, R. A.,
H. L. Rotman,
T. J. Nolan,
G. A. Schad, and D. Abraham.
1997.
Chronicity in Strongyloides stercoralis infections: dichotomy of the protective immune response to infective and autoinfective larvae in a mouse model.
Am. J. Trop. Med. Hyg.
56:640-646.
|
| 13.
|
Cupp, E. W.,
M. J. Bernardo,
A. E. Kiszewski,
M. Trpis, and H. R. Taylor.
1988.
Large scale production of the vertebrate infective stage (L3) of Onchocerca volvulus (Filarioidea: Onchocercidae).
Am. J. Trop. Med. Hyg.
38:596-600.
|
| 14.
|
Duke, B. O., and P. J. Moore.
1968.
The contributions of different age groups to the transmission of onchocerciasis in a Cameroon forest village.
Trans. R. Soc. Trop. Med. Hyg.
62:22-28[CrossRef][Medline].
|
| 15.
|
Eisenbeiss, W. F.,
H. Apfel, and T. F. Meyer.
1994.
Protective immunity linked with a distinct developmental stage of a filarial parasite.
J. Immunol.
152:735-742[Abstract].
|
| 16.
|
Elson, L. H.,
R. H. Guderian,
E. Araujo,
J. E. Bradley,
A. Days, and T. B. Nutman.
1994.
Immunity to onchocerciasis: identification of a putatively immune population in a hyperendemic area of Ecuador.
J. Infect. Dis.
169:588-594[Medline].
|
| 17.
|
Forsthuber, T.,
H. C. Yip, and P. V. Lehmann.
1996.
Induction of TH1 and TH2 immunity in neonatal mice.
Science
271:1728-1730[Abstract].
|
| 18.
|
Frank, G. R., and R. B. Grieve.
1996.
Purification and characterization of three larval excretory-secretory proteins of Dirofilaria immitis.
Mol. Biochem. Parasitol.
75:221-229[CrossRef][Medline].
|
| 19.
|
Frank, G. R.,
C. A. Tripp, and R. B. Grieve.
1996.
Molecular cloning of a developmentally regulated protein isolated from excretory-secretory products of larval Dirofilaria immitis.
Mol. Biochem. Parasitol.
75:231-240[CrossRef][Medline].
|
| 20.
|
Gallin, M.,
K. Edmonds,
J. J. Ellner,
K. D. Erttmann,
A. T. White,
H. S. Newland,
H. R. Taylor, and B. M. Greene.
1988.
Cell-mediated immune responses in human infection with Onchocerca volvulus.
J. Immunol.
140:1999-2007[Abstract/Free Full Text].
|
| 21.
|
Greene, B. M.
1992.
Modern medicine versus an ancient scourge: progress toward control of onchocerciasis.
J. Infect. Dis.
166:15-21[Medline].
|
| 22.
|
Gregory, W. F.,
M. L. Blaxter, and R. M. Maizels.
1997.
Differentially expressed, abundant trans-spliced cDNAs from larval Brugia malayi.
Mol. Biochem. Parasitol.
87:85-95[CrossRef][Medline].
|
| 23.
|
Grieve, R. B.,
D. Abraham,
M. Mika-Grieve, and B. P. Seibert.
1988.
Induction of protective immunity in dogs to infection with Dirofilaria immitis using chemically-abbreviated infections.
Am. J. Trop. Med. Hyg.
39:373-379.
|
| 24.
|
Hartmann, S.,
B. Kyewski,
B. Sonnenburg, and R. Lucius.
1997.
A filarial cysteine protease inhibitor down-regulates T cell proliferation and enhances interleukin-10 production.
Eur. J. Immunol.
27:2253-2260[Medline].
|
| 25.
|
Irvine, M.,
T. Huima,
A. M. Prince, and S. Lustigman.
1994.
Identification and characterization of an Onchocerca volvulus cDNA clone encoding a highly immunogenic calponin-like protein.
Mol. Biochem. Parasitol.
65:135-146[CrossRef][Medline].
|
| 26.
|
Jenkins, R. E.,
M. J. Taylor,
N. Gilvary, and A. E. Bianco.
1996.
Characterization of a secreted antigen of Onchocerca volvulus with host-protective potential.
Parasite Immunol.
18:29-42[CrossRef][Medline].
|
| 27.
|
Johnson, E. H.,
M. Irvine,
P. H. Kass,
J. Browne,
M. Abdullai,
A. M. Prince, and S. Lustigman.
1994.
Onchocerca volvulus: in vitro cytotoxic effects of human neutrophils and serum on third-stage larvae.
Trop. Med. Parasitol.
45:331-335[Medline].
|
| 28.
|
Johnson, E. H.,
S. Schynder-Candrian,
T. V. Rajan,
F. K. Nelson,
S. Lustigman, and D. Abraham.
1998.
Immune responses to third stage larvae of Onchocerca volvulus in interferon-gamma and interleukin-4 knockout mice.
Parasite Immunol.
20:319-324[CrossRef][Medline].
|
| 29.
|
Joseph, G. T.,
T. Huima, and S. Lustigman.
1998.
Characterization of an Onchocerca volvulus L3-specific larval antigen, Ov-ALT-1.
Mol. Biochem. Parasitol.
96:177-183[CrossRef][Medline].
|
| 30.
|
Joseph, G. T.,
J. S. McCarthy,
T. Huima,
K. F. Mair,
P. H. Kass,
M. Boussinesq,
L. Goodrick,
J. E. Bradley, and S. Lustigman.
1997.
Onchocera volvulus: characterization of a highly immunogenic Gln-rich protein.
Mol. Biochem. Parasitol.
90:55-68[CrossRef][Medline].
|
| 31.
|
Kenney, J. S.,
B. W. Hughes,
M. P. Masada, and A. C. Allison.
1989.
Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies.
J. Immunol. Methods
121:157-166[CrossRef][Medline].
|
| 32.
|
King, C. L., and T. B. Nutman.
1991.
Regulation of the immune response in lymphatic filariasis and onchocerciasis.
Immunol. Today
12:A54-A58[CrossRef][Medline].
|
| 33.
|
Lange, A. M.,
W. Yutanawiboonchai,
J. B. Lok,
M. Trpis, and D. Abraham.
1993.
Induction of protective immunity against larval Onchocerca volvulus in a mouse model.
Am. J. Trop. Med. Hyg.
49:783-788.
|
| 34.
|
Lange, A. M.,
W. Yutanawiboonchai,
P. Scott, and D. Abraham.
1994.
IL-4- and IL-5-dependent protective immunity to Onchocerca volvulus infective larvae in BALB/cBYJ mice.
J. Immunol.
153:205-211[Abstract].
|
| 35.
|
Li, B. W.,
R. Chandrashekar, and G. J. Weil.
1993.
Vaccination with recombinant filarial paramyosin induces partial immunity to Brugia malayi infection in jirds.
J. Immunol.
150:1881-1885[Abstract].
|
| 36.
|
Luder, C. G.,
H. Schulz-Key,
M. Banla,
S. Pritze, and P. T. Soboslay.
1996.
Immunoregulation in onchocerciasis: predominance of Th1-type responsiveness to low molecular weight antigens of Onchocerca volvulus in exposed individuals without microfilaridermia and clinical disease.
Clin. Exp. Immunol.
105:245-253[CrossRef][Medline].
|
| 37.
|
Lustigman, S.,
B. Brotman,
T. Huima, and A. M. Prince.
1991.
Characterization of an Onchocerca volvulus cDNA clone encoding a genus specific antigen present in infective larvae and adult worms.
Mol. Biochem. Parasitol.
45:65-75[CrossRef][Medline].
|
| 38.
|
Lustigman, S.,
B. Brotman,
T. Huima,
A. M. Prince, and J. H. McKerrow.
1992.
Molecular cloning and characterization of onchocystatin, a cysteine proteinase inhibitor of Onchocerca volvulus.
J. Biol. Chem.
267:17339-17346[Abstract/Free Full Text].
|
| 39.
|
Lustigman, S.,
T. Huima,
B. Brotman,
K. Miller, and A. M. Prince.
1990.
Onchocerca volvulus: biochemical and morphological characteristics of the surface of third- and fourth-stage larvae.
Exp. Parasitol.
71:489-495[CrossRef][Medline].
|
| 40.
|
Lustigman, S.,
J. H. McKerrow,
K. Shah,
J. Lui,
T. Huima,
M. Hough, and B. Brotman.
1996.
Cloning of a cysteine protease required for the molting of Onchocerca volvulus third stage larvae.
J. Biol. Chem.
271:30181-30189[Abstract/Free Full Text].
|
| 41.
|
Oothuman, P.,
D. A. Denham,
P. B. McGreevy,
G. S. Nelson, and R. Rogers.
1979.
Successful vaccination of cats against Brugia pahangi with larvae attenuated by irradiation with 10 krad cobalt 60.
Parasite Immunol.
1:209-216[Medline].
|
| 42.
|
Ottesen, E. A.
1995.
Immune responsiveness and the pathogenesis of human onchocerciasis.
J. Infect. Dis.
171:659-671[Medline].
|
| 43.
|
Pogonka, T.,
U. Oberlander,
T. Marti, and R. Lucius.
1999.
Acanthocheilonema viteae: characterization of a molt-associated excretory/secretory 18-kDa protein.
Exp. Parasitol.
93:73-81[CrossRef][Medline].
|
| 44.
|
Prince, A. M.,
B. Brotman,
E. H. Johnson, Jr.,
A. Smith,
D. Pascual, and S. Lustigman.
1992.
Onchocerca volvulus: immunization of chimpanzees with X-irradiated third-stage (L3) larvae.
Exp. Parasitol.
74:239-250[CrossRef][Medline].
|
| 45.
|
Robinson, K.,
T. Bellaby, and D. Wakelin.
1994.
Vaccination against the nematode Trichinella spiralis in high- and low-responder mice. Effects of different adjuvants upon protective immunity and immune responsiveness.
Immunology
82:261-267[Medline].
|
| 46.
|
Schrempf-Eppstein, B.,
A. Kern,
G. Textor, and R. Lucius.
1997.
Acanthocheilonema viteae: vaccination with irradiated L3 induces resistance in three species of rodents (Meriones unguiculatus, Mastomys coucha, Mesocricetus auratus).
Trop. Med. Int. Health
2:104-110[CrossRef][Medline].
|
| 47.
|
Soboslay, P. T.,
S. M. Geiger,
N. Weiss,
M. Banla,
C. G. Luder,
C. M. Dreweck,
E. Batchassi,
B. A. Boatin,
A. Stadler, and H. Schulz-Key.
1997.
The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection.
Immunology
90:592-599[CrossRef][Medline].
|
| 48.
|
Steel, C., and T. B. Nutman.
1993.
Regulation of IL-5 in onchocerciasis. A critical role for IL-2.
J. Immunol.
150:5511-5518[Abstract].
|
| 49.
|
Taylor, M. J.,
N. Abdel-Wahab,
Y. Wu,
R. E. Jenkins, and A. E. Bianco.
1995.
Onchocerca volvulus larval antigen, OvB20, induces partial protection in a rodent model of onchocerciasis.
Infect. Immun.
63:4417-4422[Abstract].
|
| 50.
|
Tume, C. B.,
J. L. Ngu,
J. L. McKerrow,
J. Seigel,
E. Sun,
P. J. Barr,
I. Bathurst,
G. Morgan,
C. Nkenfou,
T. Asonganyi, and G. Lando.
1997.
Characterization of a recombinant Onchocerca volvulus antigen (Ov33) produced in yeast.
Am. J. Trop. Med. Hyg.
57:626-633.
|
| 51.
|
Turaga, P. S. D.,
T. J. Tierney,
K. E. Bennett,
M. C. McCarthy,
S. C. Simonek,
P. A. Enyong,
D. W. Moukatte, and S. Lustigman.
2000.
Immunity to onchocerciasis: cells from putatively immune individuals produce enhanced levels of interleukin-5, gamma interferon, and granulocyte-macrophage colony-stimulating factor in response to Onchocerca volvulus larval and male worm antigens.
Infect. Immun.
68:1905-1911[Abstract/Free Full Text].
|
| 52.
|
Ward, D. J.,
T. B. Nutman,
G. Zea-Flores,
C. Portocarrero,
A. Lujan, and E. A. Ottesen.
1988.
Onchocerciasis and immunity in humans: enhanced T cell responsiveness to parasite antigen in putatively immune individuals.
J. Infect. Dis.
157:536-543[Medline].
|
| 53.
|
Weiner, D. J.,
D. Abraham, and R. D'Antonio.
1984.
Litomosoides carinii in jirds (Meriones unguiculatus): ability to retard development of challenge larvae can be transferred with cells and serum.
J. Helminthol.
58:129-137[Medline].
|
| 54.
|
Wong, M. M.,
M. F. Guest, and M. J. Lavoipierre.
1974.
Dirofilaria immitis: fate and immunogenicity of irradiated infective stage larvae in beagles.
Exp. Parasitol.
35:465-474[CrossRef][Medline].
|
| 55.
|
Yip, H. C.,
A. Y. Karulin,
M. Tary-Lehmann,
M. D. Hesse,
H. Radeke,
P. S. Heeger,
R. P. Trezza,
F. P. Heinzel,
T. Forsthuber, and P. V. Lehmann.
1999.
Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response.
J. Immunol.
162:3942-3949[Abstract/Free Full Text].
|
Infection and Immunity, January 2001, p. 262-270, Vol. 69, No. 1
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.1.262-270.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ford, L., Guiliano, D. B., Oksov, Y., Debnath, A. K., Liu, J., Williams, S. A., Blaxter, M. L., Lustigman, S.
(2005). Characterization of a Novel Filarial Serine Protease Inhibitor, Ov-SPI-1, from Onchocerca volvulus, with Potential Multifunctional Roles during Development of the Parasite. J. Biol. Chem.
280: 40845-40856
[Abstract]
[Full Text]
-
Kerepesi, L. A., Keiser, P. B., Nolan, T. J., Schad, G. A., Abraham, D., Nutman, T. B.
(2005). DNA Immunization with Na+-K+ATPase (Sseat-6) Induces Protective Immunity to Larval Strongyloides stercoralis in Mice. Infect. Immun.
73: 2298-2305
[Abstract]
[Full Text]
-
Tsuji, N., Suzuki, K., Kasuga-Aoki, H., Isobe, T., Arakawa, T., Matsumoto, Y.
(2003). Mice Intranasally Immunized with a Recombinant 16-Kilodalton Antigen from Roundworm Ascaris Parasites Are Protected against Larval Migration of Ascaris suum. Infect. Immun.
71: 5314-5323
[Abstract]
[Full Text]
-
MacDonald, A. J., Turaga, P. S. D., Harmon-Brown, C., Tierney, T. J., Bennett, K. E., McCarthy, M. C., Simonek, S. C., Enyong, P. A., Moukatte, D. W., Lustigman, S.
(2002). Differential Cytokine and Antibody Responses to Adult and Larval Stages of Onchocerca volvulus Consistent with the Development of Concomitant Immunity. Infect. Immun.
70: 2796-2804
[Abstract]
[Full Text]
-
McCarthy, J. S., Wieseman, M., Tropea, J., Kaslow, D., Abraham, D., Lustigman, S., Tuan, R., Guderian, R. H., Nutman, T. B.
(2002). Onchocerca volvulus Glycolytic Enzyme Fructose-1,6-Bisphosphate Aldolase as a Target for a Protective Immune Response in Humans. Infect. Immun.
70: 851-858
[Abstract]
[Full Text]